Ex­clu­sive: Iso­tope short­age forces pause of Bris­tol My­ers Phase 3 ra­dio­phar­ma­ceu­ti­cal tri­al

The de­vel­op­ment of the lead drug be­hind Bris­tol My­ers Squibb’s re­cent $4.1 bil­lion ac­qui­si­tion of Rayze­Bio has hit de­lays, be­cause of sup­ply is­sues of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.